Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease
Authors
Keywords
PCSK9, Alirocumab, Evolocumab, Dyslipidemia, Low-density lipoprotein cholesterol, Cardiovascular disease
Journal
Current Atherosclerosis Reports
Volume 21, Issue 5, Pages -
Publisher
Springer Nature
Online
2019-03-16
DOI
10.1007/s11883-019-0778-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Application of PCSK9 Inhibitors in Practice
- (2019) Tina M. Kaufman et al. CIRCULATION RESEARCH
- Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER
- (2018) Marc S. Sabatine et al. CIRCULATION
- NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
- (2018) Sotirios Tsimikas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future
- (2018) Evan M. Sisson et al. PHARMACOTHERAPY
- A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels
- (2018) Ye-Xuan Cao et al. American Journal of Cardiovascular Drugs
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2018) Scott M. Grundy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life
- (2018) Jennifer G. Robinson et al. Journal of the American Heart Association
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
- (2017) Ulf Landmesser et al. EUROPEAN HEART JOURNAL
- Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association
- (2017) Carl E. Orringer et al. Journal of Clinical Lipidology
- Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015
- (2017) Gregory A. Roth et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
- (2017) Robert P Giugliano et al. LANCET
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vaccine against PCSK9: the natural strategy from passive to active immunization for the prevention of atherosclerosis
- (2017) Fernando Civeira et al. Journal of Thoracic Disease
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers
- (2017) Alejandro Arrieta et al. JAMA Cardiology
- Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease
- (2017) Christopher P. Cannon et al. JAMA Cardiology
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
- (2016) Marc S. Sabatine et al. AMERICAN HEART JOURNAL
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
- (2016) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A review of PCSK9 inhibition and its effects beyond LDL receptors
- (2016) Dave L. Dixon et al. Journal of Clinical Lipidology
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels
- (2016) Jeffrey A. Tice et al. JAMA Internal Medicine
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More